CARMEL, Ind.--(BUSINESS WIRE)--Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today ...
Tá torthaí a d'fhéadfadh a bheith dorochtana agat á dtaispeáint faoi láthair.
Folaigh torthaí dorochtana
Aiseolas